Haisco Pharmaceutical Group revenue and financials
In the fiscal year ended December 2025, Haisco Pharmaceutical Group reported revenue of ¥4.39B (+17.91% year over year). Net income was ¥259.58M, a net margin of 5.9%.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +17.91%
- 2025 vs 2024
- Net income growth
- −34.36%
- 2025 vs 2024
- Net margin
- 5.9%
- 2024: 10.6%
How Haisco Pharmaceutical Group is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 5.7% a year on average over the last 5 years
Compound annual growth rate: from ¥3.33B in 2020 to ¥4.39B in 2025.
Revenue has grown for 4 fiscal years in a row
Each fiscal year compared with the one before, up to 2025.
Less cash than profit: free cash flow equal to 54% of net income
Totals for fiscal years 2023–2025: free cash flow ¥513.99M, net income ¥950.15M.
Shares outstanding up 4.6% in 5 years
Average diluted shares, 2020 → 2025: with more shares, each one represents a smaller stake in the company (dilution).
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 4,388 | 3,721 | 3,355 | 3,015 | 2,773 | 3,330 | 3,937 | 3,427 | 1,856 | 1,436 |
| Cost of revenue | 1,266 | 1,062 | 971 | 925 | 947 | 1,068 | 1,348 | 1,494 | 659 | 372 |
| Gross profit | 3,121 | 2,660 | 2,384 | 2,090 | 1,826 | 2,262 | 2,589 | 1,933 | 1,197 | 1,064 |
| Selling, general and administrative | 2,089 | 1,765 | 1,522 | 1,465 | 1,331 | 1,585 | 1,973 | 1,511 | 939 | 777 |
| Research and development | 804 | 624 | 517 | 448 | 431 | 406 | 235 | 204 | 119 | — |
| Operating income | 200 | 262 | 332 | 142 | 37.6 | 228 | 323 | 163 | 109 | 261 |
| EBIT | 200 | 262 | 332 | 142 | 37.6 | 228 | 323 | 163 | 109 | 261 |
| EBITDA | 462 | 502 | 544 | 317 | 184 | 333 | 411 | 235 | 172 | 322 |
| Interest expense | 32.5 | 37.8 | 42.3 | 50.9 | 27.2 | 27.3 | 24.2 | 19.8 | 25.5 | 19.1 |
| Pre-tax income | 274 | 463 | 303 | 367 | 511 | 689 | 546 | 323 | 259 | 484 |
| Income tax | 14.0 | -3.3 | 7.0 | -25.1 | -6.8 | 88.2 | 71.6 | 5.5 | 29.7 | 47.4 |
| Net income | 260 | 395 | 295 | 277 | 345 | 637 | 494 | 333 | 238 | 443 |
| Net income to common shareholders | 260 | 395 | 295 | 277 | 345 | 637 | 494 | 333 | 238 | 443 |
| Basic EPS | 0.23 | 0.35 | 0.27 | 0.26 | 0.32 | 0.59 | 0.46 | 0.31 | 0.22 | 0.41 |
| Diluted EPS | 0.23 | 0.35 | 0.27 | 0.26 | 0.32 | 0.59 | 0.46 | 0.31 | 0.22 | 0.41 |
| Average shares (basic) | 1,129 | 1,130 | 1,093 | 1,066 | 1,078 | 1,079 | 1,074 | 1,075 | 1,080 | 1,080 |
| Average shares (diluted) | 1,129 | 1,130 | 1,093 | 1,066 | 1,078 | 1,079 | 1,074 | 1,075 | 1,080 | 1,080 |
| Dividend per share | 0.27 | 0.42 | 0.20 | — | 0.19 | 0.37 | 0.09 | 0.19 | 0.28 | 0.46 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 1,875 | 1,532 | 1,564 | 1,088 | 1,299 | 1,109 | 892 | 970 | 1,065 | 935 | 752 | 971 |
| Cost of revenue | 359 | 322 | 291 | 405 | 320 | 276 | 265 | 307 | 281 | 239 | 235 | 281 |
| Gross profit | 1,516 | 1,210 | 1,273 | 683 | 979 | 833 | 627 | 664 | 783 | 696 | 517 | 690 |
| Selling, general and administrative | 644 | 581 | 473 | 590 | 576 | 512 | 412 | 507 | 477 | 420 | 359 | 387 |
| Research and development | 333 | 353 | 225 | 262 | 201 | 199 | 143 | 246 | 163 | 131 | 83.5 | 175 |
| Operating income | 633 | 259 | 567 | -177 | 188 | 113 | 79.5 | -154 | 131 | 142 | 143 | 77.0 |
| EBIT | 633 | 259 | 567 | -177 | 188 | 113 | 79.5 | -154 | 131 | 142 | 143 | 77.0 |
| EBITDA | 698 | 336 | 632 | -111 | 248 | 175 | 140 | -93.5 | 184 | 200 | 196 | 130 |
| Interest expense | 6.3 | 7.1 | 6.8 | 7.6 | 8.1 | 8.3 | 8.5 | 11.5 | 10.6 | 9.1 | 9.3 | 10.2 |
| Pre-tax income | 538 | 280 | 593 | -64.1 | 194 | 122 | 58.4 | -17.9 | 283 | 101 | 96.2 | 107 |
| Income tax | 12.4 | -16.6 | 38.3 | -28.4 | 23.3 | 7.3 | 11.8 | -32.1 | -5.7 | 29.1 | 5.5 | 12.2 |
| Net income | 525 | 297 | 555 | -35.7 | 171 | 115 | 46.6 | 13.6 | 217 | 72.8 | 92.0 | 94.4 |
| Net income to common shareholders | 525 | 297 | 555 | -35.7 | 171 | 115 | 46.6 | 13.6 | 217 | 72.8 | 92.0 | 94.4 |
| Basic EPS | 0.46 | 0.26 | 0.50 | -0.03 | 0.15 | 0.11 | 0.04 | 0.01 | 0.19 | 0.07 | 0.08 | 0.09 |
| Diluted EPS | 0.46 | 0.26 | 0.50 | -0.03 | 0.15 | 0.11 | 0.04 | 0.01 | 0.19 | 0.07 | 0.08 | 0.09 |
| Average shares (basic) | 1,134 | 1,131 | 1,109 | 1,155 | 1,119 | 1,075 | 1,165 | 1,159 | 1,164 | 1,047 | 1,149 | 1,048 |
| Average shares (diluted) | 1,134 | 1,131 | 1,109 | 1,155 | 1,119 | 1,075 | 1,165 | 1,159 | 1,164 | 1,047 | 1,149 | 1,048 |
| Dividend per share | 0.00 | 0.53 | — | 0.27 | — | — | — | 0.14 | 0.14 | 0.15 | — | 0.20 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 7,011 | 6,798 | 6,653 | 6,048 | 5,005 | 4,997 | 5,035 | 4,366 | 4,109 | 3,744 |
| Current assets | 2,834 | 2,730 | 2,641 | 2,054 | 1,548 | 2,096 | 2,075 | 1,977 | 1,814 | 2,275 |
| Cash and equivalents | 1,386 | 1,056 | 1,169 | 775 | 575 | 454 | 893 | 617 | 1,022 | 1,176 |
| Short-term investments | — | 150 | 160 | — | — | 410 | 330 | 381 | 75.1 | 5.0 |
| Receivables | 1,058 | 1,117 | 931 | 851 | 648 | 556 | 607 | 771 | 493 | 254 |
| Inventory | 307 | 272 | 281 | 346 | 260 | 224 | 189 | 149 | 146 | 121 |
| Net property, plant and equipment | 853 | 917 | 996 | 1,074 | 1,137 | 1,126 | 1,039 | 859 | 768 | 707 |
| Other intangible assets | 1,518 | 1,277 | 751 | 708 | 682 | 600 | 321 | 263 | 202 | 179 |
| Long-term investments | 178 | 147 | 232 | 422 | 381 | 399 | 456 | 434 | 200 | 156 |
| Current liabilities | 1,567 | 1,568 | 1,504 | 1,489 | 1,518 | 1,716 | 2,497 | 2,048 | 2,034 | 1,012 |
| Accounts payable | 166 | 196 | 209 | 242 | 301 | 420 | 616 | 678 | 291 | 79.2 |
| Long-term debt | 1,002 | 925 | 855 | 1,320 | 452 | 335 | 79.9 | 255 | 51.8 | 250 |
| Total debt | 1,900 | 1,668 | 1,707 | 1,627 | 797 | 335 | 430 | 285 | 252 | 272 |
| Total liabilities | 2,723 | 2,596 | 2,482 | 2,914 | 2,085 | 2,142 | 2,659 | 2,372 | 2,139 | 1,498 |
| Total equity (incl. minority) | 4,288 | 4,202 | 4,171 | 3,133 | 2,920 | 2,855 | 2,377 | 1,994 | 1,970 | 2,245 |
| Retained earnings | 2,136 | 2,180 | 2,210 | 1,807 | 1,733 | 1,787 | 1,399 | 1,109 | 1,075 | 1,329 |
| Minority interest | -2.0 | -11.1 | -9.4 | 97.7 | 78.3 | -47.6 | 5.3 | -32.4 | -15.3 | -7.7 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 9,015 | 7,877 | 7,660 | 7,011 | 7,214 | 6,992 | 6,925 | 6,798 | 6,910 | 6,459 | 6,843 | 6,653 |
| Current assets | 4,291 | 3,462 | 3,256 | 2,834 | 3,108 | 2,878 | 2,860 | 2,730 | 2,882 | 2,520 | 2,838 | 2,641 |
| Cash and equivalents | 2,576 | 1,847 | 1,810 | 1,386 | 1,405 | 1,457 | 1,298 | 1,056 | 807 | 1,004 | 1,449 | 1,169 |
| Short-term investments | 176 | 133 | 130 | — | — | — | — | — | — | — | — | — |
| Receivables | 1,124 | 1,058 | 919 | 1,058 | 1,358 | 1,042 | 1,154 | 1,117 | 1,209 | 1,110 | 957 | 931 |
| Inventory | 330 | 351 | 328 | 307 | 283 | 300 | 317 | 272 | 286 | 273 | 279 | 281 |
| Net property, plant and equipment | 861 | 836 | 854 | 853 | 863 | 860 | 883 | 917 | 988 | 944 | 970 | 996 |
| Goodwill | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — |
| Other intangible assets | 2,005 | 2,052 | 1,474 | 1,518 | 1,557 | 1,335 | 1,240 | 1,277 | 1,260 | 1,220 | 725 | 751 |
| Long-term investments | 153 | 425 | 427 | 178 | 122 | 130 | 136 | 147 | 196 | 192 | 210 | 232 |
| Current liabilities | 2,218 | 2,256 | 1,615 | 1,567 | 1,763 | 1,520 | 1,500 | 1,568 | 1,449 | 1,362 | 1,502 | 1,504 |
| Accounts payable | 248 | 272 | 157 | 166 | 160 | 165 | 175 | 196 | 172 | 138 | 145 | 209 |
| Long-term debt | 671 | 650 | 1,036 | 1,002 | 1,109 | 1,292 | 1,200 | 925 | 1,164 | 854 | 938 | 855 |
| Total debt | 2,039 | 2,015 | 2,210 | 1,900 | 2,215 | 2,219 | 2,127 | 1,668 | 1,836 | 1,532 | — | — |
| Total liabilities | 3,058 | 3,064 | 2,817 | 2,723 | 2,988 | 2,929 | 2,811 | 2,596 | 2,729 | 2,334 | 2,559 | 2,482 |
| Total equity (incl. minority) | 5,956 | 4,814 | 4,842 | 4,288 | 4,225 | 4,063 | 4,114 | 4,202 | 4,181 | 4,126 | 4,284 | 4,171 |
| Retained earnings | 2,555 | 2,630 | 2,690 | 2,136 | 2,164 | 1,998 | 2,067 | 2,180 | 2,207 | 2,152 | 2,304 | 2,210 |
| Minority interest | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -11.1 | -11.1 | -10.4 | -12.8 | -9.4 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 786 | 442 | 450 | 94.5 | 35.8 | 206 | 764 | 473 | 392 | 409 |
| Depreciation and amortization | 274 | 249 | 220 | 184 | 153 | 105 | 87.9 | 72.2 | 63.2 | 61.5 |
| Capital expenditure | -332 | -441 | -391 | -700 | -703 | -602 | -583 | -352 | -393 | -208 |
| Investing cash flow | -156 | -302 | -383 | -540 | 282 | -559 | -515 | -245 | -230 | 13.4 |
| Financing cash flow | -292 | -251 | 328 | 624 | -187 | -85.0 | 28.9 | -447 | -316 | -137 |
| Dividends paid | -333 | -422 | -42.6 | -247 | -426 | -131 | -239 | -326 | -510 | -286 |
| Share repurchases | — | — | -8.2 | -6.4 | -2.5 | -1.0 | — | — | — | — |
| Debt issued | 1,059 | 1,400 | 898 | 2,000 | 932 | 1,040 | 830 | 950 | 800 | 800 |
| Debt repaid | -1,017 | -1,309 | -1,206 | -1,153 | -819 | -1,020 | -685 | -1,015 | -621 | -611 |
| Effect of exchange rates | -6.9 | 4.9 | -1.5 | 16.9 | -6.8 | -1.8 | 1.6 | -0.7 | -3.7 | 7.9 |
| Net change in cash | 331 | -105 | 393 | 196 | 124 | -440 | 280 | -220 | -158 | 294 |
| Free cash flow | 454 | 1.4 | 58.6 | -606 | -667 | — | — | — | — | — |
| Levered free cash flow | 197 | -210 | -152 | -782 | -895 | -889 | -46.5 | -117 | 745 | -900 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 290 | 412 | 348 | 397 | 39.5 | 331 | 18.3 | 246 | 85.5 | 51.5 | 59.0 | 317 |
| Depreciation and amortization | -160 | 160 | — | 274 | -128 | 128 | — | 249 | -121 | 121 | — | 220 |
| Capital expenditure | -145 | -81.7 | -68.7 | -59.8 | -72.5 | -105 | -94.3 | -136 | -136 | -72.8 | -96.2 | -111 |
| Investing cash flow | -180 | -66.6 | -198 | -48.5 | -70.4 | -96.4 | 59.4 | 201 | -471 | -35.8 | 4.2 | -234 |
| Financing cash flow | 629 | -298 | 280 | -363 | -18.6 | -75.5 | 165 | -199 | 194 | -462 | 217 | 209 |
| Dividends paid | -607 | -306 | -6.2 | -6.8 | -7.5 | -159 | -160 | -8.8 | -172 | -233 | -8.9 | -9.2 |
| Share repurchases | — | — | — | — | — | — | — | -0.1 | — | — | — | -8.2 |
| Debt issued | 298 | 292 | 500 | 8.5 | 61.9 | 506 | 482 | 162 | 344 | 355 | 540 | 372 |
| Debt repaid | -285 | -285 | -215 | -362 | -75.7 | -418 | -161 | -355 | -56.1 | -583 | -315 | -162 |
| Effect of exchange rates | -9.8 | -10.4 | -6.7 | -3.5 | -2.1 | -0.7 | -0.5 | 8.9 | -6.0 | 1.5 | 0.5 | -5.1 |
| Net change in cash | 730 | 36.6 | 424 | -18.4 | -51.6 | 159 | 242 | 257 | -199 | -445 | 280 | 287 |
| Free cash flow | 146 | 330 | 280 | 337 | -32.9 | 226 | -76.0 | 110 | -50.4 | -21.4 | -37.2 | 206 |
| Levered free cash flow | -1.7 | 317 | 250 | 457 | -348 | 269 | -179 | 151 | -199 | 16.3 | -180 | 289 |
Financial statements of similar companies
Companies in the group: same industry, similar size
